Companies / Traws Pharma, Inc.

Traws Pharma, Inc.

Nasdaq: TRAWCIK 1130598NEWTOWN, PA

Financials · FY2024

Revenue$2.79M
Net income$9.17M
Total debt—
Cash$20.56M
Diluted EPS$0.82
Shares outstanding15.2M

Ownership

15.2M shares outstanding · as of May 12, 2026
11.5%10%+ / strategic
Ownership
10%+ / strategic11.53%1,746,518
Institutions18.77%2,843,031
Public float69.71%10,561,120

% of common shares outstanding (exact, from the latest cover-page filing). Institutions are quarterly 13F snapshots; insiders reflect current officers & directors.

Insiders 12

View all →
Insider% of sharesShares
Orbimed Advisors LLC10% owner
7.94%1,203,250
Parker Charles NolanFormerChief Financial Officer
0.10%15,393
Cautreels WernerDirector
——
Clarke TraffordDirector
——
Dukes Iain D.CEOChief Executive Officer · Director
——
Leaman John HaroldFormerDirector
——
OrbiMed Capital GP VIII LLC10% owner
——
Pauza Charles DavidChief Science Officer Virology
——
Redfield RobertFormerChief Medical Officer
——
Savchuk NikolayChief Operating Officer · Director
——

Institutional holders 25

View all →
HolderValue% of shares
Adage Capital Partners Gp, L.L.C.$1.34M4.82%
Orbimed Advisors LLC$1.11M4.00%
Squadron Master Fund LP$806.3K4.71%
Ikarian Capital, LLC$766.3K4.48%
Boothbay Fund Management, LLC$219.8K1.28%
ADAR1 Capital Management, LLC$174.5K1.02%
Geode Capital Management, LLC$141.1K0.51%
Vanguard Group Inc$98.6K0.58%
Seven Fleet Capital Management LP$55.7K0.33%
XTX Topco Ltd$47.7K0.28%

Activity

View all →
InsidersInstitutions
What insiders are doing in this stock (Form 4).
DateActorActionSecurityValueShares ΔPosition afterImpact
Apr 16, 2026Orbimed Advisors LLC
10% owner
BuyCommon Stock$998.2K+598K
+98.71%
1,203,250
7.94% of shares
high
Dec 12, 2025Parker Charles Nolan
Executive
GrantCommon Stock$0+15K
15,393
0.10% of shares
low
Mar 8, 2026Parker Charles Nolan
Executive
GrantStock Option (right to buy)—+105K
104,544
0.69% of shares
low
Dec 12, 2025Parker Charles Nolan
Executive
GrantStock Option (right to buy)—+62K
61,571
0.41% of shares
low
Oct 12, 2025Parker Charles Nolan
Executive
GrantStock Option (right to buy)—+32K
32,406
0.21% of shares
low
Apr 16, 2026Orbimed Advisors LLC
10% owner
BuySeries C Warrants (right to buy)—+1.8M
1,793,187
11.84% of shares
low
Apr 16, 2026Orbimed Advisors LLC
10% owner
BuySeries B Warrants (right to buy)—+598K
597,729
3.95% of shares
low
Apr 16, 2026Orbimed Advisors LLC
10% owner
BuySeries A Warrants (right to buy)—+598K
597,729
3.95% of shares
low

5%+ ownership events

Schedule 13D / 13G
FilerStance% of classSharesDate
Ayrton Capital LLCPassive13G/A———
Ikarian Capital, LLCPassive13G/A———
Squadron Master Fund LPPassive13G/A———
Chernett JoreyPassive13G—543,268—
Adage Capital Management, L.P.Passive13G———
Perceptive Advisors LLCPassive13G/A———
Squadron Master Fund LPPassive13G/A———

Securities

via CUSIP / OpenFIGI
SymbolTypeMarketCUSIPFIGI
TRAW——68232V884—